chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Interchange of vaccine products; COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old male patient received BNT162b2 (BNT162B2), on 16Mar2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 67 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 25Jan2021 as dose 1, single (Batch/Lot number: unknown), in left arm and on 16Nov2021 as dose 2, single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Polymyalgia rheumatica" (unspecified if ongoing). Concomitant medication(s) included: FLUOXETINE, start date: Aug2022. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 16Mar2022, outcome "unknown"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Patient took other medication in 2 weeks. Patient took COVID 19 Treatment include Paxlovid. Treatment start date was 04Aug2022. Treatment stop date was 08Aug2022. Rebound of COVID respiratory symptoms from 04Aug2022 with outcome recovering, but no other symptoms. Patient had no known allergies.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sleepy, continuous strong lower abdominal cramps, loose bowel movements with abdominal pain, cold sweat nausea, dizzy, symptoms of blacking out,  blacked out - loss of consciousness, slow speech - hard to speak, shakiness and weakness, hard to walk, slow heart rate at Emergency Room between 37-47 bpm. IV, benadryl and prednisone, sodium choloride and Iopamidol treatments provided during Emergency Care.
Patient received Moderna Bivalent instead of Primary dose. Per CDC Patient needs to be communicated no harm done but patient will need to return to receive a Pfizer full primary dose to have it count for primary. Intervals for second dose will change to scheduling 8 weeks after invalid dose.
Bad headache; This is a spontaneous report from a contactable consumer (patient herself).  A 79-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), dose 2 via an unspecified route of administration on 12Feb2021 (Batch/Lot number was not reported) as DOSE 2, SINGLE (age at vaccination was 78 years old) for COVID-19 immunization at Hospital Auxilio Mutuo. Medical history included blood pressure high ongoing. Concomitant medication(s) included losartan potassium (COZAAR) 50mg taken for hypertension, start and stop dates were not reported and clopidogrel bisulfate (PLAVIX) 50mg. Historical vaccine included bnt162b2, dose 1 via an unspecified route of administration on 22Jan2021 (Batch/Lot number was FL9261) as DOSE 1, SINGLE. On 19Feb2021, at 04:00 hrs the patient experienced bad headache. She stated that I got my second vaccine of Pfizer on Friday, February 12 and was speaking , on friday that's the second dose okay Vaccine number 2, is it possible that 8 days after that I can get the side effects, 8 days after the vaccine not on the day, not the day after but 8 days after because she having a bad headache since yesterday after 4 am in the morning I am taking Tylenol. Do you think it is possible that this headache could be a side effect of this vaccine after 8 days because I don't usually have headaches, I could say I rarely have headaches but this headache since yesterday worries me, I want to find out is this possible to have side effect from the second vaccine. When paraphrased the concern, consumer stated, correct, after 8 days. Consumer was informed about the role of Pfizer Drug safety and was also informed about Pfizer Medical Information department. When probed if County of Incidence was, consumer stated, yes (not appropriately paraphrased and clarified hence, captured). The patient stated, Expiration date I don't know, it says Pfizer 1st FL9261, the second dose says EN I think it looks like an N EN6200, it might be EN or EU, EU6200. Treatment received by the patient was acetacminophen, tylenol. The clinical outcome of the event headache was unknown.  Follow-up attempts completed. No further information expected.
Severe headache; extreme body aches; extreme fatigue; light headed when not lying down; feeling like I was going to vomit if not lying down; This is a spontaneous report from a contactable consumer (Patient). A 61-year-old (non-pregnant) female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number: EN6202), via an unspecified route of administration, administered in arm left on 26Feb2021 09:45 as single dose for covid-19 immunisation. Medical history included high cholesterol, penicillin allergy, allergies to sulfa and covid-19. Patient previously took thiomersal and had allergy from it. Concomitant medication included rosuvastatin (other medications in two weeks). The patient did not receive any other vaccines within 4 weeks. Patient had covid prior vaccination. The patient was not tested for COVID post vaccination. On 26Feb2021, the patient experienced severe headache, extreme body aches, extreme fatigue, light headed when not lying down, feeling like I was going to vomit if not lying down. The treatment was not received for adverse event. The outcome of events was recovering.   No follow-up attempts are possible. No further information is expected.
Left arm, shoulder, back soreness; Left arm, shoulder, back soreness; Left arm, shoulder, back soreness; generalized aches; chills; This is a spontaneous report from a contactable consumer (patient).  A 44-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EL3247), via an unspecified route of administration, administered in Arm Left on 15Mar2021 13:00 (at the age of 44-years-old) as dose 2, single for covid-19 immunisation. The patient medical history was not reported. Patient had no known allergies. The patient's concomitant medications were not reported. No allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: EL3247), via an unspecified route of administration, administered in Arm Left on 22Feb2021 as dose 1, single for covid-19 immunisation. On 15Mar2021, the patient experienced left arm, shoulder, back soreness, left arm, shoulder, back soreness, left arm, shoulder, back soreness, generalized aches, chills. Therapeutic measures were taken as a result of left arm, shoulder, back soreness, left arm, shoulder, back soreness, left arm, shoulder, back soreness, generalized aches, chills. Patient received treatment with Ibuprofen. The clinical outcome of events were recovering.   No follow-up attempts are needed. No further information is expected.
each time, only had sore spot to touch; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An elderly female patient (unknown if pregnant) received bnt162b2 (BNT162B2), on 26Feb2021 as dose 1, single (Lot number: EN6200) at the age of 70 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN (non-serious), outcome "unknown", described as "each time, only had sore spot to touch". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Each time, only had sore spot to touch and negative COVID-19 test (PCR) after the vaccinations.
Symptoms are fever (102 degrees F), chills, severe body aches.  Treating with ibuprofen, 600 mg every 6 hours. Outcome TBD.
Muscle pain under collar bone starting the day after the shot.  Hurts to move my right arm anywhere. Had a red sore at the injection sight the next day.  The sore only lasted a day but the collar bone muscle pain I still have.
(1) Noted vertigo approx 200AM - 1-9-21, & nausea, dizziness and weakness. Continued with improving after Day 7. Initial No pain or redness & injection site - (2) Noted -
24 hours post injection, severe headache and dizziness for 30+ hours now has subsided to persistent & transient headaches. Fever and chills hour 24- 36 which subsided and sore left arm for 1week.
after his Moderna vaccine which is his third shot since he already got 2 Pfizer doses; achy knees; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (achy knees) and INTERCHANGE OF VACCINE PRODUCTS (after his Moderna vaccine which is his third shot since he already got 2 Pfizer doses) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Sep-2021, the patient experienced ARTHRALGIA (achy knees). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (after his Moderna vaccine which is his third shot since he already got 2 Pfizer doses). At the time of the report, ARTHRALGIA (achy knees) and INTERCHANGE OF VACCINE PRODUCTS (after his Moderna vaccine which is his third shot since he already got 2 Pfizer doses) outcome was unknown.          Doses 1 and 2 were Pfizer and 3rd/booster was Moderna  No relevant concomitant medications were reported. No treatment information was provided.
PATIENT RECIEVED BOTH VACCINES AND 5 MINUTES LATER EXPERIENCED PAIN RADIATING DOWN HER BACK. CALLED 911 BUT PATIENT TOLD US TO CANCEL CALL. THEN PER PATIENT REQUEST CALLED HOSPITAL ER. SPOKE TO MEDICAL STAFF THAT PATIENT WAS HEADING DOWN RIGHT AWAY. NOT SURE THE OUTCOME YET.
Information has been received from a physician concerning an 18 year old female who on 21-JUL-1992 was vaccinated with a second dose of RECOMBIVAX HB (lot # 603897/0750V) in the left leg. The patient also received a first dose of hepatitis B virus vaccine (unspecified) on 23-JUN-1992 in hospital and a dose of ENGERIX-B (GSK, lot # ENG103O92) on 18-JAN-1993. On 19-AUG-2010 sample was collected and the patient did not have immunity to hepatitis b virus vaccine. The office spoke with the patient who said she would call when she came home for Thanksgiving break to schedule first shot. At the time of the reporting, the patient's status was unknown. Additional information has been requested.
Patient was first seen on 1/14/03 while hospitalized in the ICU. He was unable to communicate verbally and therefore the following history was obtained from his spouse, mother and his medical records. Patient was healthy with no medical problems and taking no medication prior to 12/3/02. He has received 3 anthrax vaccinations in November and December 2002. The following is an account of their sequellae. Patient went to the emergency room on 1/4/03. His records indicate he was amb with assist secondary to unsteady gait.....and verbalized complaints of dizzy, blurred vision, cough, nausea, vomiting and diarrhea 4x/day....which started 1 week ago. Vital signs were 101.4--101--20--132/30. He received IV fluids, lab work, a CXR and was discharged from the ER with the diagnosis of atypical pneumonia and gastroenteritis. Medications included azithromycin and ibuprofen with directions to follow up on 1/6/03. Records from the remaining outpatient visit(s) and admission are not available. Patient was transferred on 1/10/03 and admitted to the ICU. Diagnosis included Probable viral vs. immune mediated encephalitis. On 1/15/03 neurology consultation reports meningoencephalitis most consistent with bickerstaff (brain stem) encephalitis. Findings included oculomotor paresis, dysarthric speech, hiccups , autonomic instability and R>L LE>UE quadriparesis. The remains the current diagnosis. Elevated amylase and lipase suggest pancreatitis with unknown ideology. He has received IVIG and antiviral therapy with little improvement. Currently is relieving IV steroid therapy with minimal improvements. He also is receiving respiratory, occupational and physical therapy. On 60-day follow up report received 04/24/2003, reporter states, "Currently in rehab unit of V.A. hospital. Has debilitating sx remaining, but is now able to talk." 9/9/2003 six months after contracting encephalomyelitis post anthrax vaccine, pt remains in the hospital. Family memebers states he has made light improvement. Cannot move his right extremities, and is not walking. Can speak words but not form sentences. He still has a T-tube in place but is eating some things by mouth and feeding self. Cognitively he appears to be in tact. Annual follow up on 02/24/04: "Pt has not recovered from adverse events.  In hospital, he is speaking clearly, eating well (although gipeg still in place), has full use of left side but right side non-functional in continuous tremor. Cannot walk. Severe myostatic constructual right wrist, right foot. Continuously in tact, memory 100%, depressed. Awaiting transfer to another rehab hospital.
5 yr injections given - mom calling stating childs (L) leg was swollen from knee to groin and red.  - No temp - n pain.
This case was considered medically important for the event of febrile seizure. Information regarding Prevnar was received from a consumer regarding a 15 month old female patient who experienced a febrile seizure, hypotonia, injection site swelling, erythema, and mass; the patient additionally developed a stiff and sore leg. At 15 months of age, the patient received the fourth dose on 19 Jun 2006 in her right thigh. The patient also received a dose of an unspecified vaccine on 19 Jun 2006 in the opposite leg. The patient has a past history of febrile convulsion (occurred in January and February 2006). No previous injection site reactions to Prevnar. Indication for Prevnar was immunization. Product was administered on 19 Jun 2006. Dose regimen was 1 dose 1 time per day (intramuscular). Concomitant therapy included unspecified vaccine. After receiving the fourth dose of Prevnar in her right thigh on 19 Jun 2006, the patient woke up at 5 AM the next day with a quarter sized red spot (injection site erythema) and  pea sized bump (injection site mass) at the injection site; her leg was also swollen at the site (injection site swelling). The patient developed a temperature of 99 degrees (pyrexia) and was treated with Motrin; the temperature returned to normal. At 1 pm the child spiked a high fever between 101 and 102. Minutes later the patient experienced a seizure (febrile convulsion) which lasted 2.5 minutes. She did not loose consciousness. Muscle tone was lost for about 10 minutes (hypotonia); the child then slept for a couple of hours. The red spot was now 3 to 4 inches in diameter and the bump was now the size of a golf ball. It was noted that the mother spoke with a neurologist but a physician did not see the child.  As of 21 Jun 2006, the child still has swelling and redness in her leg and continues taking Motrin.  The redness is now half dollar size and the lump has not gone down in size. Her leg is stiff and sore, she appears to be slowed down and is favoring one leg. No additional information was available at the time of this report.
1 of 2 pts vaxed from the same lot# who exp adverse event following immun; pt recvd DTAP/MMR-3 days later, presented w/a local react which included redness, swelling-4cm in diameter, hot to touch; rx'd w/APAP & cold packs;
Has the Modern a vaccine caused osteoarthritis; This spontaneous case was reported by an other health care professional and describes the occurrence of OSTEOARTHRITIS (Has the Modern a vaccine caused osteoarthritis) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced OSTEOARTHRITIS (Has the Modern a vaccine caused osteoarthritis). At the time of the report, OSTEOARTHRITIS (Has the Modern a vaccine caused osteoarthritis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported.   No treatment information was provided by the reporter.   Reporter did not allow further contact
4FEB91 would not stand on leg - crying, temp - 100.9; 5FEB91 temp 104, pinpoint rash chest. Still would not use leg.
FLUMIST was administered in a dose of 0.2mL to patient 10/08/2008.  On 10/09/2008 patient was seen at hospital for fever, lethargy, tachypnea.  Referred to ER for further evaluation and treatment.  CXR read as patchy atelectasis vs. RML infiltrate.  Seen in follow up at hospital on 10/10/2008 and remained febrile, lethargic, and tachypneic.  Patient received albuterol in office on 10/09/2008.  Once in ER was given albuterol/ATROVENT X2.  Was discharged on zithromax and albuterol MDI.  Further follow up is pending.  10/31/08 Reviewed PCP office records of 10/8-10/20/2008 which included ER records of 10/9. FINAL DX: RML pneumonia Records reveal patient was in good health on day of vaccine & had not had reaction to previous flu vaccine.  RTC 10/9 w/fever, chills, decreased appetite, decreased activity, difficulty sleeping, crying, fatigue, irritabity, malaise, runny nose, moist cough, wheezing, diarrhea, generalized boy aches/pains, reduced urine output.  Sick contact at home w/common cold s/s.  Exam noted rales & rhonchi bilaterally, wheezing & intercostal retractions.  Tx w/nebs & sent to ER.  Tx w/oral antibiotics & nebs.  D/C to home on continued antibiotics & nebs.  Developed abdominal pain & crying after eating, irritable, diarrhea.  Sent to radiology & thought to be ileus vs early obstruction.
My daughter has excrutiating migraines and headaches daily. Lasting as long as 9 consecutive days with no sign of pressure release.
After 2nd unknown vaccine got + PCR test; This spontaneous case was reported by a nurse and describes the occurrence of SARS-COV-2 TEST POSITIVE (After 2nd unknown vaccine got + PCR test) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Dec-2021, the patient experienced SARS-COV-2 TEST POSITIVE (After 2nd unknown vaccine got + PCR test). At the time of the report, SARS-COV-2 TEST POSITIVE (After 2nd unknown vaccine got + PCR test) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Dec-2021, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided. Treatment information was not provided.   Company Comment : This case concerns a patient of unknown age and gender with no reported medical history, who experienced the unexpected adverse event of special interest of SARS-CoV-2 test positive. It is unknown the timeframe between the event and the second dose of mRNA-1273 vaccine. The rechallenge was unknown since there's no information about the first dose. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This case concerns a patient of unknown age and gender with no reported medical history, who experienced the unexpected adverse event of special interest of SARS-CoV-2 test positive. It is unknown the timeframe between the event and the second dose of mRNA-1273 vaccine. The rechallenge was unknown since there's no information about the first dose. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
blood clots both lungs; received the third dose of BNT162B2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63 year-old male patient received bnt162b2 (BNT162B2), administration date 20Dec2021 (Batch/Lot number: unknown) at the age of 63 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "known allergies: penicillin" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (Prev dose product=COVID 19, Prev dose brand=pfizer, Prev dose brand unknown=False,, Prev dose lot unknown=True,, Prev dose lot unknown reason=Not available/provided to reporter at the time of report completion,, prev dose dose number=2), for Covid-19 immunization; Bnt162b2 (Prev dose product=COVID 19,, Prev dose brand=pfizer,, Prev dose brand unknown=False,, Prev dose lot unknown=True,, Prev dose lot unknown reason=Not available/provided to reporter at the time of report completion,, prev dose dose number=1), for Covid-19 immunization. The following information was reported: IMMUNISATION (hospitalization) with onset 20Dec2021, outcome "unknown", described as "received the third dose of BNT162B2"; THROMBOSIS (hospitalization) with onset 03Jan2022 06:00, outcome "not recovered", described as "blood clots both lungs". The patient was hospitalized for thrombosis (hospitalization duration: 1 day(s)); the patient was hospitalized for immunisation (hospitalization duration: 1 day(s)). The event "blood clots both lungs" was evaluated at the emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (03Jan2022) negative, notes: type post vaccination: Unknown. Therapeutic measures were taken as a result of thrombosis. Addition information: Other vaccine in four weeks was none. Other medications in two weeks was none. Covid prior vaccination was none. Covid tested post vaccination. Ae treatment included Eliquis.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient presented to the ER on 4/16/21 for dyspnea and wheezing, diagnosed with acute COPD exacerbation/chronic bronchitis and discharged home. Pt presented to ER 4/22/21 with worsening symptoms and was admitted to the hospital for acute kidney injury, dehydration and COPD exacerbation.
Basically I got dizzy. The dizziness lasted for 6 weeks. I kept eating and forcing myself to walk and eat. Gradually the dizziness went away after 6 weeks of it.
racing heart fever chills headache body aches sore throat loss of appetite heavy period bleeding - mid cycle and not due